Equities analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to report earnings per share of ($1.10) for the current quarter, Zacks reports. Zero analysts have provided estimates for Odonate Therapeutics’ earnings. Odonate Therapeutics posted earnings per share of ($0.81) during the same quarter last year, which would suggest a negative year over year growth rate of 35.8%. The company is scheduled to issue its next quarterly earnings report on Wednesday, February 13th.
On average, analysts expect that Odonate Therapeutics will report full-year earnings of ($3.49) per share for the current financial year, with EPS estimates ranging from ($3.57) to ($3.41). For the next year, analysts forecast that the firm will post earnings of ($3.63) per share, with EPS estimates ranging from ($3.96) to ($3.30). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Odonate Therapeutics.
Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Tuesday, October 23rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.02).
Separately, Zacks Investment Research raised shares of Odonate Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Odonate Therapeutics presently has a consensus rating of “Hold” and an average target price of $31.00.
Shares of ODT stock opened at $15.31 on Monday. Odonate Therapeutics has a 52-week low of $14.06 and a 52-week high of $32.00. The stock has a market capitalization of $410.73 million and a price-to-earnings ratio of -6.63.
In related news, CEO Kevin C. Tang bought 90,000 shares of Odonate Therapeutics stock in a transaction dated Thursday, September 20th. The stock was purchased at an average cost of $19.55 per share, with a total value of $1,759,500.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin C. Tang bought 40,000 shares of Odonate Therapeutics stock in a transaction dated Wednesday, September 26th. The shares were bought at an average cost of $19.75 per share, with a total value of $790,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 273,761 shares of company stock valued at $4,882,129 over the last three months. Insiders own 49.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in ODT. Tang Capital Management LLC lifted its stake in shares of Odonate Therapeutics by 11.2% during the 3rd quarter. Tang Capital Management LLC now owns 13,796,747 shares of the company’s stock valued at $267,795,000 after buying an additional 1,384,409 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Odonate Therapeutics by 472.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,074,348 shares of the company’s stock valued at $23,722,000 after buying an additional 886,794 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Odonate Therapeutics by 375.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 81,426 shares of the company’s stock valued at $1,799,000 after buying an additional 64,310 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Odonate Therapeutics by 17.6% during the 2nd quarter. BlackRock Inc. now owns 334,259 shares of the company’s stock valued at $7,380,000 after buying an additional 50,138 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Odonate Therapeutics by 18.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock valued at $6,148,000 after buying an additional 49,528 shares in the last quarter. 92.23% of the stock is owned by hedge funds and other institutional investors.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Featured Article: How to Invest in a Bull Market
Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.